[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![AlfredoM617 Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::47191740.png) Alfredo M [@AlfredoM617](/creator/twitter/AlfredoM617) on x XXX followers
Created: 2025-07-07 19:30:19 UTC

$CLDX delivers XX% sustained response in CSU, raising bar for biologics

Barzavolumab showed XX% complete response at X months post-treatment in severe CSU patients, the most durable result in the field to date.

High retention and broad applicability position it to disrupt CSU therapy ahead of pivotal phase X readout in 2026.


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1942305194210914498/c:line.svg)

**Related Topics**
[$cldx](/topic/$cldx)

[Post Link](https://x.com/AlfredoM617/status/1942305194210914498)